Group 1 - The core viewpoint of the article indicates that Beikang Medical-B (02170) experienced a significant decline in stock price, dropping over 11% to HKD 3.44, with a trading volume of HKD 5.3292 million [1] - Beikang Medical reported a mid-year performance for 2025, revealing a revenue of RMB 101 million, which represents a year-on-year decrease of 18.76% [1] - The company also disclosed a shareholder loss of RMB 121 million, which has widened by 1.31% compared to the previous year [1] Group 2 - The revenue decline is attributed to the overall slowdown in industry growth, which has negatively impacted the company's performance [1] - Additionally, the company has proactively reduced some lower-margin projects during the reporting period, aiming to enhance overall profit levels [1]
港股异动 | 贝康医疗-B(02170)跌超11% 中期收入同比减少18.76% 亏损扩至1.21亿元